To save researchers time and resources, The Michael J. Fox Foundation has made a number of tools available to the scientific community at low cost, with rapid delivery.
Helpful Resources
-
Sponsored Tools Program
Learn more about how MJFF can help share your tools.
-
Tools Consortium
MJFF is working with industry to develop priority tools.
-
Preclinical Models
Learn more about the various in vivo models used in Parkinson's disease research.
Find a Research Tool
Filter by Tool Type or Gene/Protein Type to Organize Results
* = MJFF does not control pricing or terms of availability for this tool.
Filters
LRRK2 pS1292 Phosphospecific Antibody
Antibody
This rabbit monoclonal phosphospecific antibody was directed against human LRRK2 (aa 1250-1350, phospho S1292; the exact sequence is commercially sensitive). This antibody performs well in immunoblotting experiments from cell lysate.
Cell line stably expressing mutant LRRK2 T1348N (KI) (Type: Raw 264.7 macrophages)
Immortalized Cell
RAW 264.7 macrophage cell line expressing a T1348N mutation in LRRK2 knocked into the endogenous mouse LRRK2 protein using zinc-finger nuclease (ZFN)-assisted adeno viral vector (AAV) technology to generate a stable cell line.
Cell line stably expressing mutant LRRK2 G2019S (KI) (Type: Raw 264.7 macrophages)
Immortalized Cell
RAW 264.7 macrophage cell line expressing a G2019S mutation in LRRK2 knocked into the endogenous mouse LRRK2 protein using zinc-finger nuclease (ZFN)-assisted adeno viral vector (AAV) technology to generate a stable cell line.
We were unable to generate this cell line due to technical difficulty and have discontinued production.
Cell line stably expressing mutant LRRK2 D2017A/G2019S (KI) (Type: Raw 264.7 macrophages)
Immortalized Cell
RAW 264.7 macrophage cell line expressing a D2017A and G2019S mutation in LRRK2 knocked into the endogenous mouse LRRK2 protein using zinc-finger nuclease (ZFN)-assisted adeno viral vector (AAV) technology to generate a stable cell line.
We were unable to generate this cell line due to technical difficulty and have discontinued production.
Eif4g1 KO
Mouse Model
Mice carrying a targeted Eif4g1 mutation in which exons 24 through 28 are deleted. RRID:IMSR_JAX:024521
Alpha-Synuclein Monomer Protein
Protein
Full-Length human alpha-synuclein monomeric protein generated in vitro.
Note: This protein was used to generate alpha-synuclein filament which was then used as antigen for the MJF-14 alpha-synuclein filament-specific antibody which is also available at Abcam.
Human Alpha-Synuclein Monomer Protein for Making Pre-Formed Fibrils
Protein
Full-Length human alpha-synuclein monomeric protein specially formulated to generate pre-formed fibrils.
Note: A protocol for generating pre-formed fibrils from this monomeric protein will be included with each order.
*Discontinued for fibrils lack of seeding activity.
Total Rab 8 Antibody (Hu/Ms/Rt)
Antibody
Rabbit monoclonal antibody directed against the human and rodent total Rab 8 protein. Suitable for immunoblot and immunoprecipitation experiments. This antibody epitope was mapped to C-terminus amino acids 190-196.
Alpha-Synuclein Filament Protein
Protein
Full-Length human alpha-synuclein protein expressed in vitro and manipulated to form alpha-synuclein filaments.
Note: This filament version of alpha-synuclein was used as antigen for the MJF-14 conformation-specific rabbit monoclonal alpha-synuclein filament-specific antibody which is available at Abcam. This protein is not intended for use as a pre-formed fibril for seeding alpha-synuclein pathology in vivo or in vitro. For protein to use in an alpha-synuclein pre-formed fibril model please use the "Human alpha-synuclein monomer protein for making pre-formed fibrils" available from Proteos.
LRRK2 Antibody (MJFF3)
Antibody
Rabbit monoclonal antibody directed against wild-type LRRK2. The antibody was mapped to the LRR domain of LRRK2 (AA 1035-1239).
Have questions or need additional information?
Email tools@michaeljfox.org with questions and to suggest new tools for us to develop. Or visit our FAQ page.
"We have shown, thanks in part to MJFF, that researchers now have in their pantry the right ‘ingredients’, to... help to drive forward PD drug development.”
Heather Melrose, PhD
Mayo Clinic